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 Angiogenesis, extracellular matrix remodeling and cell migration are associated with 
cancer progression and involve at least, the plasminogen activating system and its main 
physiological inhibitor, the plasminogen activator inhibitor-1 (PAI-1). Considering the 
recognized importance of PAI-1 in the regulation of tumor angiogenesis and invasion in 
murine models of skin tumor transplantation, we explored the functional significance of PAI-
1 during early stages of neoplastic progression in the transgenic mouse model of multistage 
epithelial carcinogenesis (K14-HPV16 mice). We have studied the effect of genetic deletion 
of PAI-1 on inflammation, angiogenesis, lymphangiogenesis, as well as tumor progression. In 
this model, PAI-1 deficiency neither impaired keratinocyte hyperproliferation or tumor 
development, nor affected the infiltration of inflammatory cells and development of 
angiogenic or lymphangiogenic vasculature. We are reporting evidence for concomitant 
lymphangiogenic and angiogenic switches independent to PAI-1 status. Taken together, these 
data indicate that PAI-1 is not rate limiting for neoplastic progression and vascularization 
during premalignant progression, or that there is a functional redundancy between PAI-1 and 
other tumor regulators, masking the effect of PAI-1 deficiency in this long-term model of 
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The plasminogen activator system plays a crucial role in tumor initiation, growth, 
invasion, angiogenesis and metastasis formation 1. This proteolytic system is composed of the 
cellular receptor of urokinase (uPAR), the urokinase-type (uPA) and tissue-type plasminogen 
(tPA) activators and their specific inhibitor, the plasminogen activator inhibitor-1 (PAI-1) 2-3. 
Consistent with their role in cancer progression, high levels of uPA, PAI-1 and uPAR 
correlate with adverse patient outcome 1. A large body of clinical data led to the statement that 
uPA and PAI-1 are among the first biological prognostic factors to have their clinical value 
validated 4. PAI-1 over-expressed in tumors 5 is preferentially localized in the stromal area 6-7. 
It is expressed by various cell types including endothelial cells 8, mast cells 9, fibroblasts 10 
and myofibroblasts 11.  
Beside regulating proteolytic cascades during tissue remodeling, PAI-1 also modulates 
cell adhesion by interfering with integrin, vitronectin and low density lipoprotein receptor 
related protein (LRP) 12-15. In addition, it regulates cell proliferation 16-17 and cell apoptosis 18. 
PAI-1 is thus a multifunctional protein displaying paradoxical functions during tumor 
progression 1-3-13.  
The effect of PAI-1 on tumor biology has been explored  by using transgenic mice 
deficient for PAI-1 or over-expressing PAI-1 1-14-19. This approach clearly underlined two 
distinct effects of PAI-1 on tumor angiogenesis. While high levels of PAI-1 inhibited 
angiogenesis, physiological levels of PAI-1 were required for in vitro 20 and in vivo 
angiogenesis 21-23. In addition, PAI-1 produced by host cells plays an important role in human 
carcinoma progression 24. These data derived from experimental tumor transplantation models 
in which tumor cells were transplanted into syngeneic mice genetically modified to over-
produce or be deficient in PAI-1 expression are not consistent with the observations made 
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with de novo carcinogenesis models. Indeed, PAI-1 deficiency did not affect cancer 
progression in a transgenic mouse model of mammary carcinogenesis, the MMTV-PymT 
mice 25.  In addition, we have recently reported that PAI-1 has no effect on primary ocular 
tumor growth, but reduces brain metastasis in TRP-1/SV40 transgenic mice 26. It is not clear 
whether PAI-1-induced tumor angiogenesis represents a direct intrinsic response to invasive 
cancer cells or an early response to inflammatory assault that induces the angiogenic switch 
and subsequent malignant conversion. It has become evident that early and persistent 
inflammatory responses observed in or around developing neoplasms influence tumor 
progression 27. Several studies have shown the production of PAI-1 by immune cells such as 
macrophages and mast cells 9-28. In addition, PAI-1 inhibits the phagocytosis of apoptotic 
neutrophils (efferocytosis) and potentiates neutrophil activation 29-30. Although the implication 
of PAI-1 in inflammation is clear, the putative contribution of PAI-1 in tumor-associated 
inflammation is not fully understood. 
 With the aim at evaluating the contribution of PAI-1 during the premalignant stages of 
carcinoma development, we used a well established transgenic mouse model of de novo 
epithelial squamous cell carcinogenesis 31. In this model, expression of early region genes (E6 
and E7) of the human papillomavirus type 16 in basal keratinocytes driven by keratin 14 
promoter/enhancer induces epithelial carcinogenesis through well-defined premalignant 
stages before de novo carcinoma development (e.g. K14-HPV16 mice). K14-HPV16 mice 
develop hyperplastic skin lesions with 100% penetrance by 1 month of age that focally 
progress to dysplasia by 3 to 6 months 31. Dysplastic tissues undergo malignant conversion 
into squamous cell carcinoma (SCC) in skin of 50% of mice (FVB/n, N25), 30% of which 
metastasize into draining lymph nodes 31-32. This model has called attention to the 
involvement of proteases produced by mast cells 33 and other bone marrow-derived cells 
(neutrophils and macrophage) in the development of angiogenic vasculature and tumor 
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development 34-34-35. In the current study, we have examined the functional significance of 
PAI-1 in tumor-associated inflammation, development of angiogenic and lymphangiogenic 
vessels occurring during the course of carcinoma development.  Our data indicate that PAI-1 
independent pathways are critical for the onset and maintenance of chronic inflammation, 
angiogenesis and lymphangiogenesis during the early stages of epithelial carcinogenesis.
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MATERIAL AND METHODS 
  
Transgenic mice. 
Generation and characterization of K14-HPV16 transgenic mice on the FVB/n genetic 
background has been described previously 31-36. To generate K14-HPV16 PAI-1-/- and PAI-
1+ /+ mice, homozygous PAI-1 deficient mice and the corresponding WT mice were 
backcrossed with K14-HPV16 FVB/n transgenic mice for a minimum of 9 generations. K14-
HPV16 PAI-1-/- and PAI-1+ /+ mice with a mixed genetic background of 3.1% C57BL/6 and 
96.9% FVB/n were used. Mouse experimentation was done in accordance to the guideline of 
the University of Liege regarding the care and use of laboratory. Transgenic mice were 
sacrificed at different ages: 1 month (n=10), 4 months (n=22) and 6 months (n=28). The 
presence of the PAI-1 allele was assessed by PCR genotyping of tail DNA using 
oligonucleotide primers discriminating between the WT allele (5'- 
CTAGAGCTGGTCCAGGGCTTCAT -3’ and 5- CAGGCGTGTCAGCTCGTCTACA -3’) 
when DNA was successively amplified for 35 cycles at 95°C 2 minutes,  94°C 30 seconds, 
60°C 30 seconds, and 72°C 30 seconds.   
 
Histopathological analysis and immunohistochemistry 
Age-matched ear tissues removed from transgenic and control animals were either 
embedded in Tissue-Tek (O.C.T.TM, Sakura, Zoeterwoude, NL),  frozen at -80°C or fixed in 
buffered 1% formalin followed by dehydration through graded alcohols and xylen, and then 
embedded in paraffin. Sections (5-µm) were stained with hematoxylin/eosin for 
histopathological analysis. For immunohistochemistry, sections were treated by autoclave or 
trypsin to ensure epitope exposition and incubated 30 minutes at room temperature with H2O2 
3% (Merck, Darmstadt, Germany)
 
to block endogenous peroxydases. After brief H2O wash, a 
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blocking reagent was applied, followed up by the incubation of the primary antibodies. 
Antibodies raised against CD45 (rat anti-mouse CD45/biotin, diluted 1/1500, Pharmingen, 
San Diego, USA); Ki-67 (rat anti-mouse, diluted 1/50, DAKO, Glostrup, Denmark); Lyve-1 
(rabbit polyclonal Ab, diluted 1/1000, Bioconnect, Huissen, Netherlands) were incubated for 
1 hour at room temperature. Sections were washed in phosphate buffered saline (PBS) and 
then appropriate secondary antibodies conjugated to peroxydase or biotin for 30 minutes were 
added: rabbit anti-rat/biotin (diluted 1/300, DAKO) goat anti-rabbit/biotin (diluted 1/400, 
DAKO), rabbit anti-guinea pig/HRP (diluted 1/50, DAKO). After washes in PBS, the 
antibody-antigen complex was visualized by treatment with 3,3’-diaminobenzidine (DAB, 
DAKO, Glostrup, Denmark). Samples were counterstained with hematoxylin/eosin, washed in 
H2O, dehydrated in graded alcohols and mounted with EUKITT (Kindler GmbH, 
Ziegelhofstrasse, Freiburg). 
For double staining, tissue sections were incubated with two primary antibodies: Von 
willebrand factor (rabbit polyclonal, diluted 1/500, DAKO) and alpha smooth muscle actin (α-
SMA, mouse polyclonal, diluted 1/500, Sigma, Steinheim, Germany).  Washings were 
performed with Tris/HCL buffer (Tris/HCl 1X: 6.0 g Tris; 9 gr NaCl; 3.3 ml HCL; 1.0 L H2O; 
pH 7.6). The α-SMA staining was visualized by Fast blue prepared by mixing Fast blue (1mg) 
(Sigma-Aldrich Steinheim, Germany) with 5 dips of levamisole (DAKO) in appropriate 
buffer (Naphtol-AS-MX-phosphate 20 mg ; N,N-dimethylformamide 2 ml ; Tris/HCL 98 ml). 
Slides were mounted with Aquapolymont (polysciences, inc, Warrington). 
 
Enzyme histochemistry 
Mast cells were visualized by chloroacetate esterase (CAE) histochemistry and 
toluidin blue coloration. CAE histochemistry was performed to reveal the presence of the 
chymotrypsin-like serine esterase activity of mast cells as previously described 33. Briefly, 
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slides were deparaffinized and rehydrated in H2O. Then, 3.0 mg of Naphtol AS-D 
chloroacetate (Sigma-Aldrich, Steinheim, Germany) was dissolved in 60 µl of 
demethylformamide and 3.0 ml of buffer (8% demethylformamide, 20% Ethylene glycol 
monoethyl ether, in 80 nM Tris-maleate pH 7.5). Fast Blue BB (3mg) (Sigma-Aldrich, 
Steinheim, Germany) was added and applied on sections for 5 minutes. Slides were washed in 
PBS, dehydrated and mounted in glycerol.  
Toluidin blue coloration was used to stain mast cell granules. Sections were 
deparaffinized and rehydrated in H2O. Slides were incubated for 30 minutes in toluidin blue 
0,5% (0.5 g in HCL buffer : 948 ml H2O, 13.8 g dihydrogenophosophate de Na monohydrate, 
42 HCL, pH 0.5). Sections were washed for 15 minutes in water and incubated 2 minutes in 
nuclear red (5 g ammonium sulfate in 100 ml H2O, 0.1 g Kernechtrat). After two washings in 
2-propanol and one in xylen for 2 minutes, slides were mounted with EUKITT (Kindler 
GmbH,  Ziegelhofstrasse, Freiburg). 
 
Reverse Transcriptase-PCR analysis 
RT-PCR amplification was carried out with the GeneAmp Thermostable rTth reverse 
transcriptase RNA PCR kit (Perkin Elmer Life Sciences, Boston, MA) with specific pairs of 
primers (Table I). RT-PCR products were resolved by electrophoresis in 10% polyacrylamide 
gels and analyzed with a Fluor-S MultiImager after staining with Gelstar dye (FMC 
BioProducts, Heidelberg, Germany). RT-PCR products were quantified by normalization with 
respect to 28S rRNA. 
 
Quantification and statistical analysis 
For each time point, quantitative analysis of all stained cells was performed by 
counting cells in 5 high-power fields (40X) (except of LYVE-1 positive cells for which (20X) 
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high-power fields were used) per tissue section generated from 5 mice per neoplastic stage. 
Data presented reflect the average total count (cells or lymphatic vessels) per field from 
ventral ear leaflet. Proliferative index is defined as the proportion of tumor cells stained 
positively for Ki-67 from all epidermal cells. Quantitative analysis of the angiogenic response 
was performed by measuring the distance separating the epithelial basement membrane 
(dBM) to the 5 closest blood vessels. Five measures were realized on fields (40X) per mice 
(n=5 per neoplastic stage). To avoid problems of cutting artifact, each value was normalized 
to the thickness of the dermis (de). Results are expressed as the mean of the ratio dBM/de. 
Statistical differences between experimental groups were assessed by using Mann-Whitney 
with GraphPad Prism 4.0 (San Diego, Ca, USA.). Statistical significance was set as P<0,05. 
 
Quantification assisted by computer 
Micrographs of tissue section were digitized in the RGB space from optical 
microscope images captured at 5X magnification. In this representation, the lymphatic vessels 
stained as described above, appeared in the red colour. In order to quantify 
lymphangiogenesis, RGB images where decomposed into their red (R), green (G) and bleu 
(B) components and the red component images were thresholded using a non-parametric 
method. After this transformation, binary images were obtained in which vessels were 
represented by white pixels (intensity equal to 1) and the background by black pixels 
(intensity equal to 0). On these binary images, different parameters were evaluated: (1) the 
mean surface of vessels, (2) the number of vessels par unit of tissue area, and (3) the percent 
of tissue occupied by vessels (area density of vessels). 
Page 9 of 33
John Wiley & Sons, Inc.






PAI-1 deficiency does not affect the characteristic parameters of premalignant 
carcinogenesis in K14-HPV16 mice 
Previous studies using K14-HPV16 mice revealed an important role for the angiogenic 
switch during skin carcinoma progression 33. Given the critical role of the plasminogen 
activator plasmin system in the regulation of tumor angiogenesis as well as in the recruitment 
and activation of immune cells during pathologic tissue remodeling, we hypothesized that 
PAI-1 contributes to the recruitment of leukocytes toward neoplastic skin that fosters 
tumorigenicity. We tested this hypothesis through a genetic approach by generating a cohort 
of 30 K14-HPV16/PAI-1-/- and a cohort of 30 K14-HPV16/PAI-1+/+ and we examined several 
features of angiogenesis/lymphangiogenesis and premalignant progression in the absence and 
presence of PAI-1. 
Early neoplastic progression in K14-HPV16 mice is characterized by hyperplastic 
lesions identified by a two-fold increase in epidermal thickness and an intact granular cell 
layer with keratohyalin granules. By 4-6 months of age, dysplastic lesions are identified by 
the prominent hyperproliferative epidermis that fails to undergo terminal differentiation of 
keratinocytes. Dysplastic lesions reflect precursor sites that for emergence of invasive 
squamous cell carcinomas (SCC) that include malignant keratinocytes containing abnormal 
mitotic figures and the loss of basement membrane integrity with clear development of 
malignant cell clusters proliferating into the dermal stroma. Histopathologically, K14-
HPV16/PAI-1+/+ mice were indistinguishable from K14-HPV16/PAI-1-/- mice.  With 100% 
penetrance, HV16 mice of both genotypes developed hyperplastic skin lesions by 1 month of 
age followed by the development of dysplasias by 4 to 6 months of age. The latency and the 
incidence of the lesions observed in ear skin were independent of PAI-1 status. In both 
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genotypes, we detected 100% of hyperplastic lesions by one month of age (n = 10) and 100% 
of dysplastic lesions at 4 months (n=22) and at 6 months (n=28) of age 
As an intrinsic property of many neoplastic cell types, keratinocyte hyperproliferation 
is a characteristic of neoplastic progression in K14-HPV16 mice 33-36-37. Keratinocyte 
proliferative indices were determined by Ki67 staining in age-matched skin from K14-
HPV16/PAI-1+/+ and K14-HPV16/PAI-1-/- mice and were found to be similar in each 
neoplastic stages examined (Figure 1, P>0.1). Altogether, these observations suggest that 
PAI-1 is not involved in the control of epithelial hyperproliferation and in early stages of 
premalignant progression. 
 
PAI-1 deficiency does not affect the (lymph)angiogenic switch in K14-HPV16 mice 
In K14-HPV16 mice, changes in vascular architecture reflect the phenotypic switch to 
angiogenesis. Normal non transgenic mouse skin contains infrequent capillaries located deep 
into the dermis (Figure 2). Hyperplastic lesions showed a modest increase in capillary density 
that remains distal to the neoplastic epidermis. An increase of dilated and enlarged capillaries 
closed to the epithelial basement membrane characterizes dysplastic lesions 33-36-37. The 
distance separating epithelial basement membrane to the closest vessels was about 3 times 
lower at 4 and 6 months than at 1 month (Figure 2E, P< 0.0159). These features are indicative 
of an angiogenic switch from a vascular quiescence to the initiation of a neo-vascularization 
in early low grade lesions (hyperplasias).  
To evaluate the impact of PAI-1 deficiency on tumor vascularization, a double staining 
for Von Willebrand factor and α-SMA was performed (Figure 2A-D). α-SMA identifies 
mature vessels by presence of alpha smooth muscle actin positive mural cells. A comparison 
of vascular architecture, vessel density and distribution (Figure 2E, P>0.5) during 
premalignant progression in K14-HPV16 and K14-HPV16/PAI-1-/- mice failed to reveal any 
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differences between the two genotypes. There was also no difference in the percentage of 
mature vessels between PAI-1 proficient and deficient mice (Figure 2F, P>0.5).  
  A “lymphangiogenic switch” in tumors might represent a mirror image of an 
angiogenic switch induced by an imbalance between lymphangiogenic factors and inhibitors 
in favour of activators 38-39.  Lyve-1 staining was performed to identify lymphatic vessels and 
revealed dramatic changes in dermal lymphatic density and architecture associated with 
premalignant progression. Normal non transgenic mouse skin contained infrequent lymphatic 
vessels (Figure 3A). Hyperplastic lesions showed a modest increase in the density and 
dilatation of lymphatic vessels (Figure 3C). Dysplastic lesions contained dilated and enlarged 
vessels that were increased in number (Figure 3D). This vascular pattern is indicative of a 
lymphangiogenic switch and is in line with previous studies 40. Nevertheless, no significant 
difference in the number of lymph vessels was found between K14-HPV16 PAI-1-/- and K14-
HPV16 PAI-1+/+ in age-matched mice at 1, 4 and 6 months (Figure 3F, P>0.3). To compare 
the area of dilated vessels present in dysplatic lesions between K14-HPV16 PAI-1-/- and K14-
HPV16 PAI-1+/+, we performed a quantitative analysis on ear skin from mice at 4 months of 
age (Figure 3G and 3H, P>0.1). No difference was observed between the two genotypes. 
Altogether, these data indicate that PAI-1 deficiency does not influence either the 
angiogenic switch or the lymphangiogenic switch observed early in premalignant skin of 
K14-HPV16 mice. 
 
PAI-1 deficiency does not affect the infiltration of inflammatory cells in K14-HPV16 mice 
The K14-HPV16 transgenic model is characterized by an increased infiltration of 
CD45 positive immune cells in the successive neoplastic stages. In the opposite to 
hyperplasia, dysplastic lesions are infiltrated by mast cells, macrophages and neutrophils close 
to dilated and enlarged angiogenic vasculature 33-37-41. We profiled the infiltration of 
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leukocytes and mast cells in neoplastic tissue from K14-HPV16 PAI-1-/- and K14-HPV16 
PAI-1+/+ mice aged of 1, 4 and 6 months by immunohistochemistry. Visual detection of 
leukocytes performed by CD45 staining did not reveal differences in leukocyte infiltration 
between the two genotypes (data not shown).  
Through toluidin blue coloration, we detected mast cells in tissue. In accordance with 
previous observations, mast cell numbers increased progressively in the dermal connective 
tissue at the hyperplastic (1-month old) and dysplastic (4-6 months old) stages (Figure 4F). 
However, the number of mast cells infiltrating the lesions was similar in mice irrespective of 
their PAI-1 status (Figure 4, P>0.3). We confirmed these results by chloroacetate esterase 
(CAE) histochemistry which detects serine esterase activity in mast cells (data not shown). 
The lack of difference in immune cell infiltration between the two genotypes indicates that 
this process is not influenced by PAI-1 status. 
 
PAI-1 deficiency is not compensated by the overexpression of the main related proteases or 
inhibitors 
In order to address the possibility that other components of related proteolytic systems 
might compensate for the absence of PAI-1, we performed mRNA expression analysis by 
semi-quantitative RT-PCR of the genes encoding several protease related candidates (Table 
I). The molecules studied included components of the plasminogen/plasmin system (tPA, 
uPA, uPAR, PAI-1, PAI-2, PN-1 and MASPIN), several members of metalloproteinase 
family putatively involved in angiogenesis (MMP-2, MMP-9 and MMP-13) and angiogenic 
factors (FGF-1 and VEGF-A). This expression profiling was performed on premalignant ear 
skin tissues resected after 1, 4 and 6 months. At all time points, no significant differences 
were found in the mRNA levels of these factors in ears issued from K14-HPV16/PAI-1-/- and 
K14-HPV16/PAI-1+/+  mice (data not shown).   
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In the present study, we examined the functional significance of PAI-1 in a mouse 
model of epithelial carcinogenesis characterized by a prominent immune cell infiltration, 
activation of angiogenic vasculature and keratinocyte hyperproliferation in premalignant 
lesions. By crossing a PAI-1-null allele into the K14-HPV16 model, we generated a cohort of 
mice in which we compared neoplastic progression, angiogenesis, vessel maturity and 
leukocyte recruitment. In addition, we extended our exploration to lymphangiogenesis in 
K14-HPV16 transgenic mice deficient for PAI. The analysis of mice aged from 1, 4 and 6 
months revealed that K14-HPV16/PAI-1-/- and K14-HPV16/PAI-1+/+ were indistinguishable 
histopathologically.  
Our results confirm the occurrence of a lymphangiogenic switch occurring during the 
course of carcinogenesis. This is in line with the previous study showing a proliferation of 
lymphatic endothelial cells during the early stages of neoplastic progression 42. Large and 
dilated lymphatic vessels appeared associated with the epithelia of dysplasic lesions. The 
exact mechanisms by which tumor cells recruit and invade lymphatic vessels are still 
unknown. Since vascular remodeling associated with lymphangiogenesis and angiogenesis 
seems to involve a similar process 43, we hypothesized that PAI-1 could influence the 
lymphangiogenic reaction occurring in this multistage carcinogenesis model. However, the 
lack of PAI-1 did not affect either the lymphatic vessel density or lymphatic vessel 
architecture. This observation is in line with our previous study showing that PAI-1 
deficiency or a pharmacological inhibitor of serine proteases did not affect the endothelial cell 
sprouting from thoracic duct explants in the in vitro lymphatic ring assay 44.   
Considering the critical role of PAI-1 as a proinflammatory mediator by inhibiting the 
phagocytosis of neutrophils 30 and for potentiating Toll-like receptor 4 (TLR4)-mediated 
activation of neutrophils 29, we examined the possibility that PAI-1 might modulate immune 
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cell infiltration during carcinogenesis. Indeed immune cells and in particular mast cells are 
important contributors to the early stages of carcinogenesis. Our data indicate that PAI-1 is 
neither required for leukocyte infiltration in premalignant skin nor influences the role of 
inflammatory cells in regulating characteristics of premalignant progression during squamous 
carcinogenesis, e.g. keratinocyte hyperproliferation or angiogenesis.  While PAI-1 levels are 
associated with unfavorable outcomes during the occurrence of a number of inflammatory 
diseases such as, acute lung injury, myocardial infarction and sepsis 45-47,  PAI-1 is not a 
molecular determinant of inflammation during neoplastic progression which is considered as 
chronic disease is not significant.   
Altogether, our results indicate that PAI-1 is not required for neoplastic progression in 
K14-HPV16 transgenic mice model. They are consistent with a previous study showing that 
PAI-1 does not influence tumorigenesis, tumor growth, vascularization or metastasis in the 
MMTV-PymT model 25. However, a large body of clinical data documents the correlation 
existing between high PAI-1 levels in different types of cancer and adverse outcome 1. Does 
this mean that high PAI-1 level in cancer is an epiphenomenon? Recent studies from different 
groups do point to PAI-1 being causally involved in different steps of cancer progression and 
identify it as a potential therapeutic target 1-48-49. Indeed, PAI-1 deficiency in mice has been 
reported to dramatically reduce angiogenesis in different models of tumor transplantation 21-22. 
In addition, PAI-1 displays a pro-angiogenic effect in other angiogenesis model such as the 
mouse aortic ring assay 20 and the laser-induced choroidal neoangiogenesis model 50.  
 Such a discrepancy or apparently contradiction could be explained by some 
differences that exist between the models used. It is possible that tumor growth and 
vascularization are governed by other processes during the development of tumors upon 
carcinogenesis than those provoked by the inoculation or transplantation of tumor cells which 
represents an acute response as opposed to de novo tumor development. In carcinogenesis 
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models, the impact of a genetic ablation is evaluated during the whole process of cancer 
progression and dissemination, while it is temporally assessed in transplantation models. 
Compensatory increase in (an) other modulator(s) could take place during mice development 
and growth, but not upon transient mice challenging through tumor xenografts. Knowing the 
functional overlap between PAI-1 and other protease inhibitors, we analysed the expression 
for putative alternative inhibitors of matrix remodeling. We found that PAI-2, PN-1 and 
MASPIN are expressed in the K14-HPV16 tumors irrespective of PAI-1 status. These data are 
in line with previous findings in the MMTV-PymT 25 and TRP-1/SV40 Tag models 26. 
Alternatively, a functional overlap between MMP and PA systems has been demonstrated in 
wound healing 51. We therefore searched for other compounds of PA, MMP proteolytic 
systems and angiogenic factors (FGF1, VEGF) putatively involved in angiogenesis. However, 
we found no evidence that PAI-1 deficiency led to a compensatory increase in the levels of 
proteases (tPA, uPA, uPAR, MMP-2, MMP-9 and MMP-13) or angiogenic factors (FGF1, 
VEGF). 
Differential data generated with carcinogenesis models and tumor transplantation 
could also rely on the important influence of various host and/or tumor factors such as for 
instances, cell numbers, cell types (carcinoma versus fibrosarcoma; poorly tumorigenic versus 
aggressive tumor cells), stages of malignancy studied, expression of other modulators and site 
of inoculation 24-52. In addition, it is worth noting that the two investigations using mammary 
and skin multistage carcinogenesis models of MMTV-PymT-induced mammary gland 
carcinoma 25 and the K14-HPV-16 skin squamous carcinoma model (the present study) reveal 
the lack of PAI-1 deficiency impacts on neoplastic progression and vascular density. These 
two transgenic mice have similar FVB/N background while the pro-angiogenic and pro-
tumorigenic effects of PAI-1 were observed in C57BL/6 21-22-53 and Rag-1-/-/C57BL/6 18-24. 
There are accumulating reports of strain-related polymorphisms differentially affecting 
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phenotypes in mouse carcinogenesis models 31-54. The phenotyping of K14-HPV16 mice in 
different backgrounds revealed that C57BL/6 mice are the most resistant, developing only 
hyperplasia, whereas BALB/c develop dysplasia and papillomas and only FVB/n mice are 
permissive for malignant conversion 31. Similarly, C57BL/6 strain is resistant to the 
development of Hras-induced SCC whereas FVB/N mice are highly susceptible 55. A strong 
effect of strain on tumor latency and timing of metastasis has also been reported for PymT 
mice 56-57. In this context, a recent study has demonstrated that the anti-metastatic outcome of 
MMP-9 deficiency is dependent on the strain used 54. Only mice that had a genetic 
background derived from C57BL/6 showed reduced metastasis in the absence of MMP9, 
whereas mice of the FVB/n background showed no differences after genetic ablation of the 
enzyme. Analysis of strain-dependent modifiers has identified Sipa1 gene on chromosome 19 
and Patched gene on chromosome 13 as likely candidates for MMTV-PyMT metastasis and 
SCC susceptibility in FVB/N strain, respectively 55-58. Other loci related to tumor 
susceptibility might also be present on chromosomes 6, 9, 13, 17 and 19 59. The possibility 
that PAI-1 gene is itself the gene that is polymorphic is unlikely since it is located on 
chromosome 5. Further in-depth genetic studies are required to investigate the putative 
implication of other strain-dependent genes coding for PAI-1 partners such as proteases, ECM 
components, adhesion molecules.   
PAI-1 is a multi-functional molecule displaying, some time, opposite functions during 
cancer progression on cell migration, apoptosis, proliferation and extracellular matrix 
proteolysis. The ability of PAI-1 to regulate cell proliferation and migration has been 
attributed to its ability to control plasmin production, to modify signaling pathways and to 
bind to uPAR, vitronectin, integrin and lipoprotein receptor related protein 1-14-52-60. In 
addition, PAI-1 protects endothelial cells against apoptosis by inhibiting plasmin-mediated 
dependent activation of FAS-ligand 18 or by alterning key signaling pathways such as 
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PI3J/AKT 61. Finally, in transplantation assay, angiogenesis was dependent on the anti-
proteolytic activity of PAI-1 53. Therefore, one cannot exclude the possibility that depending 
on the model/cell used and/or mice strain, the relevant molecules such as among others, 
uPAR, vitronectin, integrins, plasmin are differently available. Based on the numerous studies 
carried out during the last decade on PAI-1 biology, it appears that tumor and host 
determinants varied from one cancer type to another. Altogether our data highlight the request 
to compare the impact of a gene deficiency in different models of experimental tumor 
transplantation and multistage carcinogenesis models in order to better understand the 
implication of a protein during the different steps of cancer progression and to determine how 
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Legend to Figures  
Figure 1: Keratinocyte proliferation is not affected in the absence of PAI-1.  
A-E: Immunohistochemical detection of Ki-67 positive cells on tissue sections of ears issued 
from K14-HPV16/PAI-1+/+ (A and C) and K14-HPV16/PAI-1-/- (B and D) mice with 
hyperplastic (A and B) and dysplastic (C and D) lesions; and on section of ears from negative 
littermate (-LM) (E). F: Quantitative analysis of the percentage of Ki-67-positive 
keratinocytes in K14-HPV16 and K14-HPV16/PAI-1-/- mice at 1, 4 and 6 months of age. 
Values represent keratinocyte proliferation which was determined as the percentage of Ki-67 
positive keratinocytes as a fraction of total keratinocytes averaged from five high-power fields 
per mouse (n=5). Error bars represent SEM. No statistically significant difference was 
observed between age-matched neoplastic tissue issued from K14-HPV16 and K14-
HPV16/PAI-1-/- (1 month P = 0.1143; 4 months P = 1; 6 months P = 0.62; Mann-Whitney 
unpaired t-test). Dashed line indicates epidermal-dermal interface. The epidermis (e), dermis 
(d), and cartilage (c) are indicated. Original magnification: 400x. Bars, 50µm. 
 
Figure 2: Tumor vascularization is not affected by PAI-1 deficiency. 
A-D: Immunocolocalization of von Willebrand factor (endothelial cells in brown) and alpha-
smooth muscle actin (pericytes in blue) in paraffin-embedded sections of age-matched 
neoplastic ear tissue of K14-HPV16 (A and C) and K14-HPV16/PAI-1-/- mice (B and D).  
E: Quantitative analysis of vessel distribution at distinct stages of neoplastic progression in 
ear tissue from K14-HPV16, K14-HPV16/PAI-1-/- and negative littermate (-LM). Values 
represent the average ratio between “dBM” and “de”. “dBM” corresponds to the distance 
separating epithelial basement membrane and the 5 closest blood vessels. “de” is the thickness 
of dermis. Errors bars represent SEM (1 month P = 0;8857; 4 months P = 0;547; 6 months P 
= 0.9166; Mann-Whitney unpaired t-test). F: Quantitative analysis of vessel maturity at 
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distinct stages of neoplastic progression in ear tissue from K14-HPV16, K14-HPV16/PAI-1-/- 
and negative littermate (-LM). Values represent the percentage of vessels covered by 
pericytes (% α-SMA positive vessels) evaluated on five high-power fields per mouse and five 
mice per category. Errors bars represent SEM. No statistically significant differences were 
observed between age-matched neoplastic tissues between K14-HPV16 and K14-
HPV16/PAI-1-/- (1 month P = 0.3429 ; 4 months P = 0.8413; 6 months P = 0.3457; Mann-
Whitney unpaired t-test). Original magnification: 400x. Bars, 50µm. 
 
 
Figure 3: The lymphangiogenic switch during squamous epithelial carcinogenesis is 
independent of PAI-1 status. 
A-F: Immunohistochemical detection of lymphatic vessels by Lyve-1 staining in normal skin 
of negative littermate (-LM) (A); hyperplastic lesions (B, C), dysplastic lesions (D, E) of ear 
skin issued from K14-HPV16/PAI-1+/+ mice (B, D) and K14-HPV16/PAI-1-/- mice (C, E). F-
H: Quantification of ear vascularization performed by determining the vessel density (number 
of vessels per area) (1 month P = 0.5386; 4 months P = 0.3321; 6 months P = 0.2530; Mann-
Whitney unpaired t-test) (F); the area density of vessels (percentage of tissue occupied by 
lymphatic vessels) (P = 0;1508; Mann-Whitney unpaired t-test) (G) and the mean surface of 
lymphatic vessels (P = 0.4206; Mann-Whitney unpaired t-test) (H). In all quantifications, 
values represent average values from five high-power fields per mouse and five mice per 
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Figure 4: The infiltration of neoplastic skin by mast cells is not affected by PAI-1-
deficiency.  
A-E: Detection of mast cell infiltration by toluidin blue coloration on hyperplastic ear skin (A 
and B), in dysplastic ear skin (C and D) from K14-HPV16 (A and C) and K14-HPV16/PAI-1-
/- (B and D) and in normal ear skin (E). F: Quantitative analysis of mast cells at distinct stages 
of neoplastic progression in ear tissue from K14-HPV16, K14-HPV16/PAI-1-/- and negative 
littermate (-LM). Values represent the number of mast cells averaged from five high-power 
fields per mouse and five mice per experimental group. Error bars represent SEM (1 month P 
= 0.3314; 4 months P = 0.9166; 6 months P = 0.92 ; Mann-Whitney unpaired t-test). Original 
magnification: 400x. Bars, 50µm. 
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  Forward primer (5’→3’) Reverse primer (5’→3’) Cycles (n) 
MMP-2 5’-AGATCTTCTTCTTCAAGGACCGGTT-3’  5’-GGCTGGTCAGTGGCTTGGGGTA-3’  27 
MMP-9 5’-GCGGAGATTGGGAACCAGCTGTA-3’ 5’-GACGCGCCTGTGTACACCCACA-3’ 35 
MMP-13 5’-ATGATCTTTAAAGACAGATTCTTCTGG-3’  5’-TGGGATAACCTTCCAGAATGTCATAA-3’ 33 
TIMP-1 5’-CATCCTGTTGTTGCTGTGGCTGAT-3’ 5’-GTCATCTTGATCTCATAACGCTGG-3’ 30 
TIMP-2 5’-CTCGCTGGACGTTGGAGGAAAGAA-3’ 5’-AGCCCATCTGGTACCTGTGGTTCA-3’ 25 
TIMP-3 5’-CTTCTGCAACTCCGACATCGTGAT-3’ 5’-CAGCAGGTACTGGTACTTGTTGAC-3’ 27 
uPA 5’-ACTACTACGGCTCTGAAGTCACCA-3’ 5’-GAAGTGTGAGACTCTCGTGTAGAC-3’ 30 
tPA 5’-CTACAGAGCGACCTGCAGAGAT-3’ 5’-AATACAGGGCCTGCTGACACGT-3’ 27 
uPAR 5’-ACTACCGTGCTTCGGGAATG-3’ 5’-ACGGTCTCTGTCAGGCTGATG-3’ 30 
PAI-1 5’-CTAGAGCTGGTCCAGGGCTTCAT -3’ 5’- CAGGCGTGTCAGCTCGTCTACA -3’ 30 
PAI-2 5’-CTCAAACCAAAGGTGAAATCCCAA-3’ 5’-GGTATGCTCTCATGCGAGTTCACA-3’ 30 
Maspin 5’-CACAGATGGCCACTTTGAGGACAT-3’ 5’-GGGAGCACAATGAGCATACTCAGA-3’ 27 
PN-1 5’- GGTCCTACCCAAGTTCACAGCTGT-3’ 5’-AGGATTGCAGTTGTTGCTGCCGAA-3’ 27 
VEGF-A 5’-CCTGGTGGACATCTTCCAGGAGTA-3’ 5’-CTCACCGCCTCGGCTTGTCACA-3’ 33 
FGF-1 5’-GGCTGAAGGGGAGATCACAACCTT-3’ 5’-CATTTGGTGTCTGCGAGCCGTATA-3’ 29 
28s 5’-GTTCACCCACTAATAGGGAACGTGA-3’ 5’-GATTCTGACTTAGAGGCGTTCAGT-3’ 15 
Table 1. Sequences of primers used for RT-PCR studies. 
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